Vascular Interventional Advances (VIVA)

The VIVA Foundation is a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education, research, advocacy, and collaboration. It hosts the VIVA (Vascular InterVentional Advances) and The VEINS (Venous Endovascular INterventional Strategies) annual conferences. The VIVA Foundation also presents the Vascular Leaders Forum and collaborates with other industry-leading groups to move the field forward. 

RSS icon

New $1 million research initiative supports early career vascular disease investigator research

The American Heart Association and VIVA Physicians, Inc. announced today a two-year $1 million grant program to support research initiatives in vascular disease and career development opportunities for early career investigators at the post-doctoral level.

Data Further Reinforce IN.PACT Admiral DCB as Frontline Option to Address Treatment Challenges in PAD

DUBLIN and LAS VEGAS — September 12, 2017 — Medtronic plc (NYSE: MDT) data announced today reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD).

Thumbnail

Out on a Limb: Tackling the PAD Knowledge Gap to Save Legs & Lives

Peripheral artery disease is under scrutiny as the number of endovascular interventions has soared. In a field where clinical evidence is sparse, experts are asking how the financial and societal costs of revascularization compare with amputating the problem and whether early detection and treatment could save lives, limbs and perhaps healthcare dollars.

Shockwave Medical’s lithoplasty system achieves primary endpoint in single-arm study

A single-arm study found that all of the patients with moderate or severely calcified peripheral lesions who received the lithoplasty system achieved the primary efficacy endpoint of procedural success.

Medtronic Valiant Captivia Demonstrates Safety and Efficacy at Three Years

Medtronic announced new data, demonstrating safety and efficacy at three years in acute complicated Type B aortic dissection patients treated with the Valiant Captivia Thoracic Stent Graft System. Ali Azizzadeh, MD, FACS, University of Texas Health Science Center in Texas presented the new clinical data in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2016.

Shockwave Medical Announces FDA Clearance of the Company’s Lithoplasty® System, the First and Only Technology to Use Sound Waves to Treat Calcified Peripheral Artery Disease

Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced clearance from the U.S. Food and Drug Administration (FDA) of the Lithoplasty System for the treatment of calcified plaque in patients with peripheral artery disease (PAD).

Viva Physicians announces late-breaking clinical trial lineup

Viva Physicians, a non-profit organization devoted to vascular interventions and medicine, announced the late-breaking clinical trials for its annual conference. The meeting will take place from September 18 to 22 in Las Vegas at the Wynn resort and casino.

Thumbnail

Data Drought: The Struggle to Build Evidence in Vascular Medicine & Intervention

How VIVA Physicians is working to answer questions about treatment of vascular disease.

Displaying 9 - 16 of 26

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup